Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00994123 · ClinicalTrials.gov registry record · Phase 1
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Merrimack Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 162
- Enrollment target
NCT00994123: Completed Phase 1 study, sponsored by Merrimack Pharmaceuticals.
NCT00994123 is a Phase 1 study that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 162 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (170% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00994123, a Phase 1 study, has completed, sponsored by Merrimack Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 162 participants
- Enrollment target
Study Summary
A Phase 1-2 study of MM-121 in combination with standard therapy for non-small cell lung cancer (NSCLC).
Primary Outcome
To establish the safety of escalating doses of MM-121 in combination with erlotinib in order to determine the recommended phase 2 dose of the combination for the second part of the study. Dose-escalation conducted using standard 3+3 model to determine maximum tolerated dose. Reports of Dose-Limiting Toxicities (DLTs) were assessed to determine the MTD.
Interventions
- DRUG Erlotinib
- DRUG MM-121
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2010-02 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
What the finished NCT00994123 record still lists
NCT00994123 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (170% higher).
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT00994123 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00994123 about?
NCT00994123 is a clinical study titled "A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer". A Phase 1-2 study of MM-121 in combination with standard therapy for non-small cell lung cancer (NSCLC).
What is the current status of trial NCT00994123?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 162 participants. The study started on 2010-02. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00994123?
The interventions under investigation include: Erlotinib (DRUG), MM-121 (DRUG).
Who is sponsoring clinical trial NCT00994123?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00994123's enrollment target sits among peer trials
162 336th of 2000 higher than 1,661 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia